Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Other Accumulated Expenses (2022 - 2026)

HeartSciences filings provide 5 years of Other Accumulated Expenses readings, the most recent being $84898.0 for Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses fell 17.09% to $84898.0 in Q1 2026 year-over-year; TTM through Jan 2026 was $84898.0, a 17.09% decrease, with the full-year FY2025 number at $29927.0, down 12.36% from a year prior.
  • Other Accumulated Expenses hit $84898.0 in Q1 2026 for HeartSciences, down from $148572.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $389186.0 in Q3 2022 to a low of $1220.0 in Q2 2022.
  • Median Other Accumulated Expenses over the past 5 years was $153596.0 (2023), compared with a mean of $151498.1.
  • The widest YoY moves for Other Accumulated Expenses: up 3883.28% in 2023, down 45.62% in 2023.
  • HeartSciences' Other Accumulated Expenses stood at $291670.0 in 2022, then plummeted by 45.62% to $158620.0 in 2023, then increased by 9.47% to $173644.0 in 2024, then decreased by 14.44% to $148572.0 in 2025, then plummeted by 42.86% to $84898.0 in 2026.
  • The last three reported values for Other Accumulated Expenses were $84898.0 (Q1 2026), $148572.0 (Q4 2025), and $215334.0 (Q3 2025) per Business Quant data.